Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 4763: Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway

Hirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, Tadaaki Yamada, Shuichi Sakamoto, Manabu Kawada and Seiji Yano
Hirokazu Taniguchi
Divisions of Medical Oncology, Cancer Research Institute, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinji Takeuchi
Divisions of Medical Oncology, Cancer Research Institute, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koji Fukuda
Divisions of Medical Oncology, Cancer Research Institute, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadaaki Yamada
Divisions of Medical Oncology, Cancer Research Institute, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shuichi Sakamoto
Institute of Microbial Chemistry, Numazu, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manabu Kawada
Institute of Microbial Chemistry, Numazu, Japan.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seiji Yano
Divisions of Medical Oncology, Cancer Research Institute, Kanazawa, Japan;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2016-4763 Published July 2016
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA

Abstract

Small-cell lung cancer (SCLC) is one of the most aggressive malignancy, characterized by rapid growth and metastatic spread to multiple organs. Approximately 70% of SCLC patients have distant metastases at the diagnosis. Recent studies reported some genomic aberrations in SCLC and several molecular target drugs have been evaluated in clinical trials. However, no molecular target agents have been approved yet for SCLC.

Hepatocyte growth factor (HGF), also known as scatter factor, is only one ligand for MET receptor. HGF/MET pathway plays the crucial role in the growth of various types of cancers. The purpose of this study is to examine the role of HGF/MET pathway activation in SCLC and to evaluate therapeutic potential of MET inhibitors, including crizotinib and golvatinib, against metastasized SCLC.

We used eight human SCLC cell lines. Expression of HGF and MET was evaluated by ELISA and western blot, respectively. Cell viability was examined by MTT assay. Four cell lines produced discernible levels of HGF and four cell lines expressed phosphorylated MET, respectively. MET inhibitors, crizotinib and golvatinib, remarkably inhibited the viability of three cell lines, SBC-5, DMS273 and DMS273B1. Knockdown of either MET or HGF by specific siRNA suppressed the growth of these cell lines, indicating that HGF/MET pathway activation is essential for survival of these SCLC cell lines. These observations suggest that MET-TKIs may be useful for a subset of SCLC with aberrant HGF/MET pathway activation.

We recently established in vivo imaging model of multiple organ metastasis (including liver and bone metastases) with SBC-5 cells. We are now evaluating the anti-metastatic effect of MET-TKIs, crizotinib and golvatinib, in the in vivo imaging model. At the annual meeting, we will present the results of MET-TKI treatment and discuss their potential against multiple-organ metastasis produced by SCLC with aberrant HGF/MET pathway activation.

Citation Format: Hirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, Tadaaki Yamada, Shuichi Sakamoto, Manabu Kawada, Seiji Yano. Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 4763.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 76 (14 Supplement)
July 2016
Volume 76, Issue 14 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 4763: Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 4763: Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway
Hirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, Tadaaki Yamada, Shuichi Sakamoto, Manabu Kawada and Seiji Yano
Cancer Res July 15 2016 (76) (14 Supplement) 4763; DOI: 10.1158/1538-7445.AM2016-4763

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 4763: Targeted therapy by MET inhibitors against small-cell lung cancer with aberrant activation of HGF/MET pathway
Hirokazu Taniguchi, Shinji Takeuchi, Koji Fukuda, Tadaaki Yamada, Shuichi Sakamoto, Manabu Kawada and Seiji Yano
Cancer Res July 15 2016 (76) (14 Supplement) 4763; DOI: 10.1158/1538-7445.AM2016-4763
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract LB-236: Risk of tMDS/AML after chemotherapy for first primary lymphoid malignancy, 2000-2013
  • Abstract LB-001: Impact of direct physician engagement with racial/ethnic minorities for oncology clinical trial access and accrual model
  • Abstract LB-107: EV-TRACK: transparent reporting and centralizing knowledge of extracellular vesicles to support the validation of extracellular vesicle biomarkers in cancer research
Show more 3

Poster Presentations - Molecular Characterizations of Tumors and Translational Studies

  • Abstract 4773: Gene-targeted apoptosis as a novel therapeutic strategy for HER2-positive breast cancer
  • Abstract 4760: Efficacy of EGFR/HER2 duel-kinase inhibitors in PDX models harboring known and novel HER2-mutations
  • Abstract 4766: Establishment of drug sensitivity and resistance testing using focused drug libraries to develop targeted therapies for patients with leukemia
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement